IBRX
Immunitybio Inc
NASDAQ: IBRX · HEALTHCARE · BIOTECHNOLOGY
$6.96
+0.00% today
Updated 2026-04-29
Market cap
$7.19B
P/E ratio
—
P/S ratio
63.45x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$2 – $12
Volume
27.9M
Immunitybio Inc (IBRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-169.00%
ROE
0.00%
ROA
-36.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $600000.00 | $-2.05M | 57.83% | -378.17% | -341.17% |
| 2014 | $641000.00 | $-6.21M | 100.00% | -969.11% | -969.27% |
| 2015 | $236000.00 | $-236.88M | 100.00% | -101,218.64% | -100,371.19% |
| 2016 | $44000.00 | $-120.81M | 100.00% | -282,954.55% | -274,565.91% |
| 2017 | $45000.00 | $-96.42M | 100.00% | -220,266.67% | -214,273.33% |
| 2018 | $47000.00 | $-96.23M | 6,717.02% | -209,338.30% | -204,736.17% |
| 2019 | $43000.00 | $-65.79M | -20,858.14% | -155,597.67% | -152,997.67% |
| 2020 | $605000.00 | $-221.85M | 100.00% | -36,509.09% | -36,669.59% |
| 2021 | $934000.00 | $-346.79M | 100.00% | -35,361.88% | -37,129.55% |
| 2022 | $240000.00 | $-416.57M | 100.00% | -146,374.17% | -173,569.58% |
| 2023 | $622000.00 | $-583.20M | 100.00% | -58,239.55% | -93,761.41% |
| 2024 | $14.74M | $-413.56M | 100.00% | -2,334.23% | -2,804.77% |
| 2025 | $113.29M | $-351.40M | 99.34% | -226.00% | -310.18% |